Neuraxis

Neuraxis Cost of Goods Sold

The Cost of Goods Sold (COGS) of Neuraxis (NRXS) as of Nov 22, 2026 is 562,916.00 USD. In the previous year, Cost of Goods Sold (COGS) was 362,002.00 USD — a change of 55.50% (higher).

Cost of Goods Sold

562,916.00USD

YoY

55.50%

Last updated:

Cost of Goods Sold (COGS) of Neuraxis is 2025 562,916.00 USD. Cost of Goods Sold (COGS) of Neuraxis was 2024 362,002.00 USD. It decreases by 55.50% higher compared to the previous year.

The Neuraxis Cost of Goods Sold history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cost of Goods Sold
Date
Cost of Goods Sold
Jan 1, 2020
481,089.00 USD
Jan 1, 2021
467,656.00 USD
Jan 1, 2022
297,060.00 USD
Jan 1, 2023
303,345.00 USD
Jan 1, 2024
362,002.00 USD
Jan 1, 2025
562,916.00 USD
The Neuraxis Cost of Goods Sold history
YEARCost of Goods SoldYoY
562,916.00USD+55.50%
362,002.00USD+19.34%
303,345.00USD+2.12%
297,060.00USD-36.48%
467,656.00USD-2.79%
481,089.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Cost of Goods Sold (COGS) of Neuraxis is 562,916.00 USD in 2025.

Cost of Goods Sold (COGS) of Neuraxis changed from 362,002.00 USD to 562,916.00 USD, representing a 55.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cost of Goods Sold (COGS) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

COGS represents the direct costs attributable to the production of goods sold. It includes material and labor costs directly tied to the product.

Cost of Goods Sold (COGS)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cost of Goods Sold (COGS)'s Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neuraxis

All Key Metrics — Neuraxis